作为药物载体的DNA:超分子结构中的水性β-环氧德克斯通道
1Department of Chemistry, Materials, and Chemical Engineering "Giulio Natta", Milano, Italy.
Chemistry (Weinheim an der Bergstrasse, Germany)
|February 15, 2026
概括
与奎尔塞丁复合的β-cyclodextrins (βCDs) 在DNA上形成有序的结构. 这些由键稳定的超分子复合体,为基于DNA的新型药物输送系统提供了洞察力.
科学领域:
- 生物物理学的生物物理.
- 超分子化学 超分子化学
- 纳米技术纳米技术
背景情况:
- 使用含DNA的超分子复合体的药物递送系统对细胞内运输具有前景.
- 药物载体DNA相互作用的分子机制尚不清楚.
研究的目的:
- 为了研究DNA上β-cyclodextrin (βCD) -quercetin包含复合物的形成和吸附.
- 阐明控制这些超分子相互作用的分子机制.
主要方法:
- 使用了原子分子力学和分子动力学模拟.
- 对DNA结构上包含复合体的形成,吸附和自我聚合的分析.
主要成果:
- βCD-quercetin的包容复合体沿着DNA沟形成有序的疏水性通道.
- βCDs之间的键稳定了围绕DNA的长距离,线状的超分子结构.
- 分子间相互作用驱动着粘附过程.
结论:
- 这项研究揭示了βCD-quercetin复合物对DNA吸附的详细分子机制.
- 这些发现为设计基于DNA的先进药物输送平台提供了基础.
- 了解这些超分子相互作用是治疗应用的关键.
相关概念视频
Site-Targeted Drug Delivery Systems: Polymeric Carriers
17
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
17
Modified-Release Drug Delivery Systems: Rate-Programmed II
6
Rate-programmed drug delivery systems release drugs in a controlled manner to maintain therapeutic levels. Three main designs include reservoir, matrix, and hybrid systems.Reservoir systems consist of a drug core enclosed within a membrane that controls drug release. In non-swelling reservoir systems, polymers like ethyl cellulose or polymethacrylates are used. These do not hydrate in aqueous media and control release through membrane thickness, porosity, or insolubility. This type includes...
6
Clathrin Coated Vesicles
9.5K
Clathrin-coated vesicles use endocytosis to transport receptors and lysosomal hydrolases from the Golgi to the lysosome in the late secretory pathway. Clathrin-mediated endocytosis was the first described endocytic process, and Clathrin-coated vesicles remain one of the most well-studied transport vesicles. The molecular machinery that generates clathrin-coated vesicles comprises over 50 proteins that precisely coordinate vesicle formation. Cell surface receptors concentrated in indented sites...
9.5K
Bioavailability Enhancement: Drug Stability Enhancement and GI Retention
227
Body:Improving a drug's stability in the gastrointestinal (GI) tract is paramount for enhancing its bioavailability and therapeutic effectiveness. Various strategies are employed to protect the drug from the harsh gastric milieu and to ensure its release and absorption at the desired site within the GI tract.Polymer coatings are one such method used to shield drugs from the stomach's acidic environment. By preventing premature drug release, these coatings improve the bioavailability of unstable...
227
Cellular Membranes and Drug Transport
1.7K
Drugs must traverse multiple biological barriers, such as multi-layered skin, single-layered intestinal epithelium, and the plasma membrane, to reach their target sites within the body. The plasma membrane, a highly structured composite of phospholipids, carbohydrates, and proteins, is the cell's protective boundary, facilitating selective substance exchange.
Phospholipids arrange themselves into a bilayer, with hydrophilic heads oriented outward and hydrophobic tails facing inward.
Phospholipids arrange themselves into a bilayer, with hydrophilic heads oriented outward and hydrophobic tails facing inward.
1.7K
Modified-Release Drug Delivery Systems: Site-Targeted
18
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
18


